Rabeprazole

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Rabeprazole
   1. Pharmacist Assessment Report
   2. Rabeprazole: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Rabeprazole: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Rabeprazole, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The two known uses listed below are recorded as relations in the knowledge graph, and no approval was found for them.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	2
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
Smouldering systemic mastocytosis
lymphoadenopathic mastocytosis with eosinophilia

Australia Market Information

Licence	Product	Dosage form	Status
11670F	Rabeprazole Sandoz	Tablet containing rabeprazole sodium 20	Valid

Safety Considerations

• Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not label text): liver disease, gallbladder disease, osteoporosis, postmenopausal osteoporosis and bone fracture. These should be checked against the TGA-approved Product Information.
• Drug Interactions: 100 interactions were identified, and the first 20 are summarised here.
  • Major: acalabrutinib, atazanavir.
  • Moderate: amikacin, amphetamine, amphotericin B (several formulations), apalutamide, aprepitant, armodafinil, bosutinib, bendroflumethiazide and others.
  • Minor: acetylsalicylic acid, axitinib.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---